| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -17,636 | -15,997 | -16,997 | -36,798 |
| Depreciation | 157 | 156 | 155 | 311 |
| Stock-based compensation | 3,924 | 3,435 | 3,590 | 7,524 |
| Amortization of premiums on investment securities, net | 147 | 512 | 767 | 1,974 |
| Non-cash lease expense | 69 | -8 | -7 | -6 |
| Deferred financing costs | NaN | 0 | 0 | 427 |
| Prepaid expense and other assets | 287 | 880 | -459 | 955 |
| Accounts payable and other liabilities | -2,511 | 1,840 | 2,405 | 241 |
| Net cash used in operating activities | -16,431 | -11,966 | -11,162 | -31,230 |
| Purchases of investment securities | 52,589 | 87,624 | 78,075 | 126,080 |
| Proceeds from maturities of investment securities | 45,000 | 76,075 | 84,585 | 154,225 |
| Purchases of property and equipment | 0 | 34 | 0 | 159 |
| Net cash (used in) provided by investing activities | -7,589 | -11,583 | 6,510 | 27,986 |
| Issuance of common stock through employee stock purchase plan | NaN | 288 | 0 | 361 |
| Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs | 19,907 | 24,847 | NaN | NaN |
| Proceeds from the exercise of stock options | 27 | 182 | 37 | 23 |
| Net cash provided by financing activities | 19,934 | 25,317 | 37 | 384 |
| Net (decrease) increase in cash and cash equivalents | -4,086 | 1,768 | -4,615 | -2,860 |
| Cash and cash equivalents at beginning of period | 16,856 | 15,088 | 22,563 | NaN |
| Cash and cash equivalents at end of period | 12,770 | 16,856 | 15,088 | NaN |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)